Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android


The FDA approved sotorasib (AMG 510) for the treatment of KRAS G12C mutated lung cancers after progression on first-line treatment.

Atezolizumab (PD-L1 inhibitor) can be given for 1 year post–adjuvant chemotherapy for resected stage II to IIIA NSCLC, based on a phase 3 trial showing improvement in disease-free survival compared with adjuvant chemotherapy without atezolizumab. For stage III NSCLCs, a phase 3 trial has shown improved survival outcomes by adding durvalumab (PD-L1 inhibitor) as consolidation therapy post–definitive chemoradiation.

Five-year follow-up data for patients with 50% or greater PD-L1 expression show that patients who received pembrolizumab versus chemotherapy alone had improved median overall survival of 26 months versus 13 months.

Skoulidis F et al. N Engl J Med. [PMID: 34096690]

Reck M et al. J Clin Oncol. [PMID: 33872070]

Felip E et al. Lancet. [PMID: 34555333]


For patients who complete neoadjuvant chemoradiation and undergo a complete resection but are found to have residual cancer in the resection specimen, a year of adjuvant immunotherapy with nivolumab is recommended.

Ahmed O et al. Clin Gastroenterol Hepatol. [PMID: 33813072]


Triplet chemotherapy for resectable gastric cancer is recommended for patients who are fit but is associated with more toxicity than doublet chemotherapy.

The development of immunotherapy represents a promising strategy in a selected patients with locally advanced and metastatic gastric cancer. Testing for microsatellite instability-high (MSI-H), mismatch repair deficiency (dMMR), PD-1, and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy.

ASGE Standards of Practice Committee; Jue TL et al. Gastrointest Endosc. [PMID: 33168194]

de Steur WO et al; CRITICS investigators. Ann Oncol. [PMID: 33227408]

Kawazoe A et al. Jpn J Clin Oncol. [PMID: 33241322]

Ng SP et al. Ann Surg Oncol. [PMID: 33689079]


For advanced/unresectable disease, first-line doublet chemotherapy is standard. Two trials suggest value from adding bevacizumab to chemotherapy. Pembrolizumab is an accepted treatment modality for mismatch repair-deficient tumors.


For the 50% of patients with metastatic CRC who have KRAS/NRAS/BRAF wild-type tumors, cetuximab and panitumumab (monoclonal antibodies to the epithelial growth factor receptor, in combination with chemotherapy, can extend median survival by 2 to 4 months compared with chemotherapy alone. For the 5% to 10% with BRAF V600E sequence variations, targeted combination therapy with BRAF and EGFR inhibitors extend overall survival to 9.3 months, compared with 5.9 months for those receiving standard chemotherapy.

In ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.